Mechanisms of scleroderma-induced lung disease

Proceedings of the American Thoracic Society

Volumn 4, Issue 5, 2007, Pages 434-438

  Du Bois, Roland M ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Autoantibody; Epithelial mesenchymal transition; Genetics; Systemic sclerosis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; AUTOANTIBODY; CONNECTIVE TISSUE GROWTH FACTOR; DNA TOPOISOMERASE II AUTOANTIBODY; ENDOTHELIN 1; HLA DP ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PENTETATE TECHNETIUM TC 99M; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RANTES; THROMBIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ALLELE; AUTOIMMUNE DISEASE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DISEASE ASSOCIATION; EPITHELIUM CELL; FIBROGENESIS; FIBROSING ALVEOLITIS; GENETIC PREDISPOSITION; GENOTYPE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTERSTITIAL PNEUMONIA; LUNG BIOPSY; LUNG FIBROSIS; MYOFIBROBLAST; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; PULMONARY HYPERTENSION; SCLERODERMA; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TH2 CELL;

EPITHELIAL CELLS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION, PULMONARY; IMMEDIATE-EARLY PROTEINS; INDIANS, NORTH AMERICAN; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MAJOR HISTOCOMPATIBILITY COMPLEX; OKLAHOMA; OSTEONECTIN; PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC;

EID: 34548739767     PISSN: 15463222     EISSN: None     Source Type: Journal    
DOI: 10.1513/pats.200608-152MS     Document Type: Conference Paper

References (42)

1. Black CM. Scleroderma: clinical aspects. J Intern Med 1993;234:115-118.
2. Masi AT, Rodnan GP, Medsger TA Jr. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-590.
3. Goh NS, du Bois RM. Interstitial disease in systemic sclerosis. In: Wells AU, Denton CP, editors. Pulmonary involvement in systemic autoimmune diseases. London: Elsevier; 2004. pp. 181-208.
4. Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, Haslam PL, Vassilakis DA, Black CM, du Bois RM. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002;165:1581-1586.
5. Henault J, Tremblay M, Clement I, Raymond Y, Senecal JL. Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis. Arthritis Rheum 2004;50:3265-3274.
6. Arnett FC, Howard RF, Tan F, Moulds JM, Bias WB, Durban E, Cameron HD, Paxton G, Hodge TJ, Weathers PE, et al. Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma: association with an Amerindian HLA haplotype. Arthritis Rheum 1996;39:1362-1370.
7. Zhou X, Tan FK, Wang N, Xiong M, Maghidman S, Reveille JD, Milewicz DM, Chakraborty R, Arnett FC. Genome-wide association study for regions of systemic sclerosis susceptibility in a Choctaw Indian population with high disease prevalence. Arthritis Rheum 2003;48:2585-2592.
8. Briggs DC, Vaughan RW, Welsh KI, Myers A, Dubois RM, Black CM. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet 1991;338:661-662.
9. Gilchrist FC, Bunn C, Foley PJ, Lympany PA, Black CM, Welsh KI, du Bois RM. Class II HLA associations with autoantibodies in scleroderma: a highly significant role for HLA-DP. Genes Immun 2001;2:76-81.
10. 1 in cultured normal human fibroblasts. Arthritis Rheum 2005;52:257-261.
11. Lagan AL, Pantelidis P, Renzoni EA, Fonseca C, Beirne P, Taegtmeyer AB, Denton CP, Black CM, Wells AU, du Bois RM, et al. Single-nucleotide polymorphisms in the SPARC gene are not associated with susceptibility to scleroderma. Rheumatology (Oxford) 2005;44:197-201.
12. Tan FK, Tercero GM, Arnett FC, Wang N, Chakraborty R. Examination of the possible role of biologically relevant genes around FBN1 in systemic sclerosis in the Choctaw population. Arthritis Rheum 2003;48:3295-3296.
13. Avila JJ, Lympany PA, Pantelidis P, Welsh KI, Black CM, du Bois RM. Fibronectin gene polymorphisms associated with fibrosing alveolitis in systemic sclerosis. Am J Respir Cell Mol Biol 1999;20:106-112.
14. Harrison NK, Myers AR, Corrin B, Soosay G, Dewar A, Black CM, du Bois RM, Turner-Warwick M. Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis 1991;144:706-713.
15. + T-cell repertoire in the lungs of patients with systemic sclerosis. Hum Immunol 1996;48:84-97.
16. + γ/δ T-cells in systemic sclerosis patients. Ann N Y Acad Sci 1995;756:382-391.
17. Majumdar S, Li D, Ansari T, Pantelidis P, Black CM, Gizycki M, du Bois RM, Jeffery PK. Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a quantitative study of open lung biopsies. Eur Respir J 1999;14:251-257.
18. Luzina IG, Atamas SP, Wise R, Wigley FM, Xiao HQ, White B. Gene expression in bronchoalveolar lavage cells from scleroderma patients. Am J Respir Cell Mol Biol 2002;26:549-557.
19. + T cells from scleroderma patients. Arthritis Rheum 2003;48:2262-2274.
20. Scala E, Pallotta S, Frezzolini A, Abeni D, Barbieri C, Sampogna F, De Pita O, Puddu P, Paganelli R, Russo G. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004;138:540-546.
21. Meloni F, Caporali R, Marone Bianco A, Paschetto E, Morosini M, Fietta AM, Bobbio-Pallavicini F, Pozzi E, Montecucco C. Cytokine profile of bronchoalveolar lavage in systemic sclerosis with interstitial lung disease: comparison with usual interstitial pneumonia. Ann Rheum Dis 2004;63:892-894.
22. Silver RM, Miller KS, Kinsella MB, Smith EA, Schabel SI. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 1990;88:470-476.
23. Kissin EY, Lemaire R, Korn JH, Lafyatis R. Transforming growth factor β induces fibroblast fibrillin-1 matrix formation. Arthritis Rheum 2002;46:3000-3009.
24. Varga J, Rosenbloom J, Jimenez SA. Transforming growth factor β (TGF β) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J 1987;247:597-604.
25. Deguchi Y, Kishimoto S. Spontaneous activation of transforming growth factor-β gene transcription in broncho-alveolar mononuclear cells of individuals with systemic autoimmune diseases with lung involvement. Lupus 1991;1:27-30.
26. 1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders. Histopathology 1994;24:145-150.
27. 1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol 1995;22:1876-1883.
28. 3 mRNA transcripts in normal and fibrotic human lung. Thorax 2001;56:549-556.
29. Leask A, Holmes A, Abraham DJ. Connective tissue growth factor: a new and important player in the pathogenesis of fibrosis. Curr Rheumatol Rep 2002;4:136-142.
30. Renzoni EA, Abraham DJ, Howat S, Shi-Wen X, Sestini P, Bou-Gharios G, Wells AU, Veeraraghavan S, Nicholson AG, Denton CP, et al. Gene expression profiling reveals novel TGFβ targets in adult lung fibroblasts. Respir Res 2004;5:24.
31. Chambers RC, Leoni P, Blanc-Brude OP, Wembridge DE, Laurent GJ. Thrombin is a potent inducer of connective tissue growth factor production via proteolytic activation of protease-activated receptor-1. J Biol Chem 2000;275:35584-35591.
32. Ohba T, McDonald JK, Silver RM, Strange C, Leroy EC, Ludwicka A. Scleroderma bronchoalveolar lavage fluid contains thrombin, a mediator of human lung fibroblast proliferation via induction of platelet-derived growth factor α-receptor. Am J Respir Cell Mol Biol 1994;10:405-412.
33. 1 induces α-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 1993;122:103-111.
34. 1 promotes the morphological and functional differentiation of the myofibroblast. Exp Cell Res 2000;257:180-189.
35. 1. Am J Respir Cell Mol Biol 1999;21:658-665.
36. Highland KB, Silver RM. New developments in scleroderma interstitial lung disease. Curr Opin Rheumatol 2005;17:737-745.
37. 99mTc-DTPA predicts the clinical course of fibrosing alveolitis. Eur Respir J 1993;6:797-802.
38. Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of interstitial pneumonitis activity: sialylated carbohydrate antigen KL-6. Chest 1989;96:68-73.
39. Denton CP, Zheng B, Evans LA, Shi-wen X, Ong VH, Fisher I, Lazaridis K, Abraham DJ, Black CM, de Crombrugghe B. Fibroblast-specific expression of a kinase-deficient type II transforming growth factor β (TGFβ) receptor leads to paradoxical activation of TGFβ signalling pathways with fibrosis in transgenic mice. J Biol Chem 2003;278:25109-25119.
40. 1: potential role in idiopathic pulmonary fibrosis. Am J Pathol 2005;166:1321-1332.
41. Willis BC, du Bois RM, Borok Z. Epithelial origin of myofibroblasts during fibrosis in the lung. Proc Am Thorac Soc 2006;3:377-382.
42. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003;112:1776-1784.